CRABP1 and amyotrophic lateral sclerosis: Therefore, targeting CRABP1–CaMKII signalosome provides an attractive strategy in managing neurological diseases, such as ALS, where aberrant Ca2+ signaling/excitotoxicity can be especially detrimental to vulnerable neuron populations such as MNs [43,45].